Suppr超能文献

[阿扎胞苷成功治疗伴有嗜中性皮病的骨髓增生异常综合征]

[Myelodysplastic syndrome with neutrophilic dermatosis successfully treated with azacitidine].

作者信息

Kudo Daisuke, Shimizu Misayo, Kuroda Akihiro, Suyama Takuya, Shinagawa Atsushi, Ito Syusaku

机构信息

Department of Hematology/Oncology, Hitachi General Hospital.

Department of Dermatology, Hitachi General Hospital.

出版信息

Rinsho Ketsueki. 2017;58(6):607-612. doi: 10.11406/rinketsu.58.607.

Abstract

A 66-year-old male underwent prednisolone (PSL) therapy of 13 mg/day for rheumatoid arthritis (RA). Antiphospholipid antibody syndrome, neutrophilic dermatosis (ND), and myelodysplastic syndrome (MDS) developed. Treatment of MDS required red cell concentrate transfusion, and second courses of azacitidine therapy (75 mg/m daily, intravenous injection for 7 consecutive days) led to hematologic remission. Furthermore, ND improved early after the start of azacitidine therapy, making it possible to decrease the dose of PSL. After 12th courses of azacitidine therapy, treatment was discontinued and the long-term remission of MDS and ND has been maintained. During the course, the level of matrix metalloproteinase-3, as a marker of RA, also decreased. There are few case reports of MDS in which azacitidine was effective for autoimmune diseases, including ND. We report the present case.

摘要

一名66岁男性因类风湿关节炎(RA)接受每日13毫克泼尼松龙(PSL)治疗。随后出现了抗磷脂抗体综合征、嗜中性皮病(ND)和骨髓增生异常综合征(MDS)。MDS的治疗需要输注红细胞浓缩液,阿扎胞苷治疗的第二个疗程(每日75毫克/平方米,连续7天静脉注射)使血液学缓解。此外,阿扎胞苷治疗开始后不久ND有所改善,从而有可能降低PSL的剂量。在阿扎胞苷治疗的第12个疗程后,治疗停止,MDS和ND维持长期缓解。在此过程中,作为RA标志物的基质金属蛋白酶-3水平也有所下降。关于阿扎胞苷对包括ND在内的自身免疫性疾病有效的MDS病例报告很少。我们报告了本病例。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验